2m 2m 2m 2m 2m 2m 2m
- $289.5MMarket Cap
- -9.91%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
ALPHA TEKNOVA (TKNO)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 46
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Key Executives
- Stephen Gunstream
- Matthew C. Lowell
- Damon A. Terrill
- Jennifer Henry
Current Ownership Distribution
- Institutions112.7M (74.60%)
- Mutual Funds21.9M (14.47%)
- Insiders16.5M (10.93%)
- Other0 (0.00%)